Gedeon Richter has submitted a biosimilar version of Roche’s RoActemra (tocilizumab) to the European Medicines Agency, the company announced last night. This move could lead to the approval and release of the drug in 2026.

The introduction of more biosimilar products is a crucial component of Richter’s strategy to transition its Biotech unit from a loss to a profit-making entity. This shift is a key element of Richter’s recently disclosed 10-year plan.

RBC has forecasted the launch of two biosimilars in the coming 18 months, RGB-14 (denosumab) and RGB-19 (tocilizumab).

In Friday’s trading, Richter’s shares experienced a 2% decrease.